Global Cephalosporin Drugs Market Size Study & Forecast, by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, Fifth-generation), by Prescription (Prescription Drugs, OTC Drugs), and Regional Analysis, 2023-2030

Global Cephalosporin Drugs Market Size Study & Forecast, by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, Fifth-generation), by Prescription (Prescription Drugs, OTC Drugs), and Regional Analysis, 2023-2030

Global Cephalosporin Drugs Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 2.75% during the forecast period 2023-2030. Cephalosporin, a versatile β-lactam antibiotic with a broad spectrum, is derived from the fungus Acremonium. It is primarily employed for treating a wide range of bacterial infections, such as skin infections, otitis media, pneumonia, staph infections, tonsillitis, strep throat, bronchitis, and gonorrhea, serving both therapeutic and preventive purposes. First-generation cephalosporins are particularly effective against gram-positive bacteria such as Staphylococcus and Streptococcus, playing a crucial role in preventing hospital-acquired infections and treating skin and soft tissue infections. In contrast, second to fifth-generation drugs are specifically designed to combat gram-negative bacteria. These medications are also used in managing drug-induced allergic conditions, particularly in individuals with penicillin allergies. The Cephalosporin Drugs Market is expanding because of factors such as the increasing prevalence of infectious diseases, rise in government initiatives and healthcare policies, growing funding for the development of antibiotics, and expanding access to healthcare services.

In addition, the market is fueled by escalating demand for antimicrobials across various medical conditions, the surge in infectious diseases such as HIV and tuberculosis, and augmented funding for antibiotic research and development. For instance, the World Health Organization's October 2021 report highlighted tuberculosis as a global concern, with approximately 10 million reported cases in 2020, concentrated heavily in eight countries including India, China, and Indonesia. Additionally, a rapid spread of infectious diseases, as evidenced by a World Health Organization survey conducted from January 24 to February 6, 2022, recorded around 12,368 cases of influenza viruses. This surge highlights the growing need for cephalosporins to address infectious diseases, contributing to market growth. The increased consumption of cephalosporins, coupled with their widespread availability and the rising demand for over-the-counter medications, further drives market expansion. Thus, these aforementioned factors are propelling the growth of the Cephalosporin Drugs Market during the estimated period. Moreover, the advancements in drug development activities, as well as the surge in demand for anti-microbials in various indications present various lucrative opportunities over the forecast years. However, the stringent regulatory guidelines, along with side effects associated with cephalosporin are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cephalosporin Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the escalating infectious disease rates, growing healthcare spending, and a sizable population, availability of advanced healthcare infrastructure and skilled medical professionals. According to the Center for Disease Control and Prevention (CDC), in 2020, the United States recorded approximately 7,174 new tuberculosis cases, reflecting a rate of 2.2 per 100,000 individuals, highlighting a significant concern. Consequently, the mounting burden of infectious diseases is expected to propel market expansion. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing number of surgical procedures, hospitalizations, and healthcare-associated infections, the growing geriatric population, and favorable government initiatives to combat antimicrobial resistance are significantly propelling the market demand across the region.

Major market players included in this report are:
Baxter International Inc.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Lupin Pharmaceuticals Inc.
Macleods Pharmaceuticals Ltd
Mankind Pharma Ltd.
Merck & Co. Inc
Pfizer Inc.
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Company

Recent Developments in the Market:
 In March 2023, Hikma Pharmaceuticals PLC (Hikma) introduced Cefazolin injection to treat a range of bacterial infections, including those affecting the joints, skin, blood, bone, and genitalia.
 In July 2022, Mast introduced Ceftobiprole 5µg to its MASTDISCS Antimicrobial Susceptibility Test range. Ceftobiprole (Zevtera/Mabelio) is a 5th generation Cephalosporin with broad-spectrum capabilities, approved in various European countries for treating Community Acquired Pneumonia (CAP) and Hospital-Acquired Pneumonia (HAP). With potent activity against Methicillin Resistant Staphylococcus aureus (MRSA) and a favorable safety profile, Ceftobiprole is a valuable option for targeted empirical therapy
 In June 2022, Shionogi & Co., Ltd., GARDP, and the Clinton Health Access Initiative (CHAI) signed a collaborative agreement to increase access to cefiderocol in over 70% of nations globally. This deal should broaden the company's product offering internationally and enhance income generation.

Global Cephalosporin Drugs Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Generation, Prescription, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Generation:
First-generation
Second-generation
Third-generation
Fourth-generation
Fifth-generation

By Prescription:
Prescription Drugs
OTC Drugs

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Baxter International Inc.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Lupin Pharmaceuticals Inc.
Macleods Pharmaceuticals Ltd
Mankind Pharma Ltd.
Merck & Co. Inc
Pfizer Inc.
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Company

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.